Lupin launches Meloxicam capsules

December 28, 2020 | Monday | News

Meloxicam capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc, and indicated for management of osteoarthritis (OA) pain

Source credit: Shutterstock

Source credit: Shutterstock

Lupin Limited a global pharmaceutical company, announced the launch of Meloxicam capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.

Meloxicam capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex® capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc, and indicated for management of osteoarthritis (OA) pain.

Meloxicam capsules (RLD: Vivlodex®) had an annual sales of approximately $11 million in the US (IQVIA MAT October 2020).

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy